LAKE FOREST, Ill., May 11 /PRNewswire-FirstCall/ -- Hospira, Inc.
(NYSE: HSP), a leading global specialty pharmaceutical and
medication delivery company, today held its 2010 Annual Meeting of
Shareholders in Denver, Colo. The
agenda included votes on two items and an update on the company's
progress during 2009.
"2009 was a great year for Hospira," said Christopher B. Begley, chairman and chief
executive officer. "We advanced our key businesses, we improved
Hospira's financial profile and we fueled profitable growth for our
future. In 2010, we continue to execute our strategy and advance
innovative solutions to help our customers and patients address
their pressing needs. Through Project Fuel, our optimization
initiative, we are transforming Hospira, driving towards
top-ranking financial performance and increased shareholder
value."
During the annual meeting, shareholders:
- elected the following directors: Connie
R. Curran, R.N., Ed.D. Heino von Prondzynski, and
Mark F. Wheeler, M.D., M.P.H. all
Class III directors whose terms expire in 2013; and
- ratified the appointment of Deloitte & Touche LLP as
Hospira's auditors for 2010.
A full description of the above matters was included in
Hospira's proxy statement related to the meeting. The proxy
statement is available on Hospira's Web site at
www.hospirainvestor.com, as are Mr. Begley's remarks.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing Wellness™. As
the world leader in specialty generic injectable pharmaceuticals,
Hospira offers one of the broadest portfolios of generic acute-care
and oncology injectables, as well as integrated infusion therapy
and medication management solutions. Through its products, Hospira
helps improve the safety, cost and productivity of patient care.
The company is headquartered in Lake
Forest, Ill., and has approximately 13,500 employees. Learn
more at www.hospira.com.
SOURCE Hospira, Inc.